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Summary
Background: The importance of primary biliary cholangitis as an indication for liver transplan-
tation has probably been influenced by the introduction of therapies, and changes in selection
criteria and disease epidemiology.
Aims: To assess the time trends in liver transplantation for primary biliary cholangitis and to
evaluate the characteristics of the patient population during the past three decades.
Methods: Patients undergoing liver transplantation from 1986 to 2015 in centres reporting to
the European Liver Transplantation Registry were included. We excluded combined organ
transplantations and patients <18 years. Trends were assessed using linear regression models.
Results: We included 112 874 patients, of whom 6029 (5.3%) had primary biliary cholangitis.
After an initial increase in the first decade, the annual number of liver transplantation for pri-
mary biliary cholangitis remained stable at around 200. The proportion of liver transplantations
for primary biliary cholangitis decreased from 20% in 1986 to 4% in 2015 (P < 0.001). Primary
biliary cholangitis was the only indication showing a consistent proportional decrease through-
out all decades. From the first to the third decade, the age at liver transplantation increased
from 54 (IQR 47‐59) to 56 years (IQR 48‐62) and the proportion of males increased from 11%
to 15% (both P < 0.001).
Conclusions: We have found a proportional decrease in primary biliary cholangitis as indica-
tion for liver transplantation. However, despite treatment with ursodeoxycholic acid and
improved disease awareness, the absolute annual number of liver transplantations has sta-
bilised.
Authors’ complete affiliations are listed in Appendix section.
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1 | INTRODUCTION
Primary biliary cholangitis (formerly called primary biliary cirrhosis,
PBC) is a chronic cholestatic liver disease, characterised by progres-
sive intrahepatic bile duct destruction which may eventually lead to
fibrosis, cirrhosis, and death.1 In the 20 years following the first
human liver transplantation in 1963, PBC was the leading indication
for liver transplantation in Europe, accounting for 30%‐50% of all
liver transplantations.2 However, despite increasing disease preva-
lence,3,4 PBC is no longer a leading indication for liver transplanta-
tion. The recent change in nomenclature is figurative for the
changed prognosis of patients over the past decades.5
Today, patients are usually diagnosed with PBC at an early stage,
which allows for timely onset of therapy, often resulting in improve-
ment of biochemical parameters and prognosis.6–12 However,
patients who respond incompletely still have a significantly impaired
prognosis compared to an age‐ and sex‐matched general popula-
tion.13,14 In case of liver failure, liver transplantation remains the
only therapeutic option to prevent premature death. However,
changes in selection criteria for liver transplantation and in the epi-
demiology, as well as the introduction of ursodeoxycholic acid
(UDCA) as an effective treatment, may have impacted the relative
importance of PBC as indication for transplantation. Previous Euro-
pean studies that have assessed trends in liver transplantation for
PBC reported a decrease in transplantations. However, these studies
were either single centre or single‐country studies, often covered rel-
atively short study periods, or are now outdated.15–17 A long‐term
European‐wide study is currently lacking, as is data on possible
changes over time in the characteristics of the subgroup of patients
with PBC who still require liver transplantation.
Thus, the primary aim of this study was to assess the time trends in
the number of liver transplantations for PBC across Europe over the past
three decades, both in absolute and proportional measures. Secondly,
we aimed to evaluate the potential changes in characteristics of patients
with PBC undergoing liver transplantation during this time period.
2 | MATERIALS AND METHODS
2.1 | Study design
Patient data were obtained through the European Liver Transplanta-
tion Registry (ELTR). ELTR data are available to all the members of
the European Liver and Intestine Transplant Association (ELITA) for
research purposes, once the study protocol is approved. All patients
transplanted in ELTR‐associated centres from 1 January 1986 until
31 December 2015, were assessed. Patients who underwent com-
bined organ transplantation and patients aged under 18 years at the
time of liver transplantation were excluded. In order to more thor-
oughly assess patients’ characteristics, all patients with PBC who
were listed for liver transplantation at any of the three liver trans-
plantation centres in the Netherlands during the study period were
included for in‐depth analyses.
This study was conducted in accordance with the principles of
the Declaration of Helsinki. The protocol was approved by ELITA
and the Dutch Organ Transplant Registry. The protocol was
reviewed and approved by the institutional research board of the
corresponding centre, and at each participating centre, in accordance
with local regulations.
2.2 | Data collection
Data collected for our primary analyses included date of birth, gender,
date of listing for liver transplantation, date of liver transplantation,
and the biochemical parameters used to calculate the model for end‐
stage liver disease (MELD) score at the time of transplantation.18 Indi-
cations for liver transplantation by primary and secondary aetiologies
were classified using the ELTR aetiology codes. Patients with PBC
were identified using these aetiology codes, including patients with
PBC‐autoimmune hepatitis (PBC‐AIH) overlap syndrome (defined as
interface hepatitis on liver histology combined with alanine amino-
transferase (ALT) ≥5× upper limit of normal or IgG ≥2×)19 and patients
with an additional diagnosis of hepatocellular carcinoma. For our in‐
depth analyses, all patients with PBC listed for liver transplantation
during the study period in the Netherlands were identified using the
Dutch Organ Transplant Registry (NOTR) and the three local liver
transplantation centre registrations. For these patients, the following
additional data were extracted from medical records: date of PBC
diagnosis, date of initiation of UDCA treatment when applicable, sec-
ondary indication for liver transplantation and biochemical parameters
including total bilirubin, alkaline phosphatase (ALP), aspartate amino-
transferase (AST), albumin, creatinine, and INR at time of diagnosis, at
time of initiation with UDCA treatment, at 1 year after treatment initi-
ation, at time of listing for liver transplantation, and at time of liver
transplantation. These measures were used to calculate the Barcelona,
Paris I, and GLOBE response criteria for patients 1 year after the initial
start of UDCA treatment.14,20,21 The secondary indication for liver
transplantation was classified as either liver failure, an additional diag-
nosis of hepatocellular carcinoma, or quality of life (QOL) (defined as
therapy‐refractory fatigue or pruritus after following the EASL guideli-
nes for management of cholestatic liver diseases or a mean score of
≥4 in the fatigue or pruritus domain of the PBC‐40).22 The biochemical
disease stage was determined based on serum albumin and bilirubin
concentrations according to the Rotterdam criteria, classifying PBC
into early (normal total bilirubin and normal albumin), moderately
advanced (abnormal total bilirubin or abnormal albumin), or advanced
disease (abnormal total bilirubin and abnormal albumin).10 UDCA
treatment status was classified as “yes” when patients were treated
with UDCA at time of listing, independent of treatment duration,
dosage, and/or combination with other treatment.
2.3 | Calculations
MELD scores provided in the registry data were used when available,
also when this concerned patients with MELD exception points. If no
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MELD score was declared, we calculated it based on laboratory values
using the following formula: 0.957 * Natural logarithm (ln) of (crea-
tinine in mg/dL) + 0.378 * ln (bilirubin in mg/dL) + 1.120 * ln (INR) +
0.643.18 For our analyses, we preferred declared MELD scores over
laboratory MELD scores when available, since laboratory MELD scores
do not take into account possible MELD score exception points.
To exclude erroneous data, for all biochemical parameters included
in the MELD score, clinically feasible minimum and maximum values
were defined based on clinical expertise. Values exceeding these ranges
were excluded from analyses and considered missing. The ranges were
defined as follows: serum creatinine 0.01‐11.3 mg/dL (20‐1000 µmol/
L), serum bilirubin 0.06‐58 mg/dL (1‐1000 µmol/L), INR 0.5‐10, and
albumin 10‐60 g/L. The MELD score was considered to range from a
minimum of 6 to a maximum of 40.23
2.4 | Statistical analyses
Linear regression least‐square models were used to assess trends
over time for our primary endpoints. For normally distributed contin-
uous variables, the one‐way ANOVA was used for the comparison
of more than two groups. In case of skewed distribution of continu-
ous variables, the Mann‐Whitney U test was used for the compar-
ison of two groups, and the Kruskal‐Wallis test for more than two
groups. For categorical variables, differences between the three dec-
ades were compared using the chi‐squared test. For comparative
purposes, the study period was divided into three groups according
to the date of transplantation. Every group represents the time span
of one decade (1 January 1986‐31 December 1995; 1 January
1996‐31 December 2005; 1 January 2006‐31 December 2015).
Statistical analysis was performed using SPSS version 21. A
P‐value of less than 0.05 was considered statistically significant.
3 | RESULTS
3.1 | Study population
Between 1 January 1986 and 31 December 2015, 128 802 patients
underwent liver transplantation in 166 European Liver Transplantation
Registry centres. We excluded 15 928 patients because of combined
organ transplantation or age <18 years at time of liver transplantation.
Thus, 112 874 patients were included in our study population. Of this
total, 6029 (5.3%) were transplanted for PBC. In comparison, 26 861
(23.8%) were transplanted for viral hepatitis, 23 207 (20.6%) for alco-
holic cirrhosis, 20 047 (17.8%) for cancers, and 9226 (8.2%) for
autoimmune diseases of the liver other than PBC. Patient characteris-
tics for those transplanted for PBC are presented in Table 1.
3.2 | Primary Indications for liver transplantation—
changes in absolute and proportional numbers
In 1986, 283 liver transplantations were performed, as compared to
5646 in 2015. The number of transplantations increased by 184 per
year (95% CI 183‐184, P < 0.001) (Figure 1A). The absolute annual
number of transplantations for PBC peaked to 279 in 1994.
TABLE 1 Characteristics of patients transplanted for PBC in ELTR centres from 1986 to 2016
Decade of liver transplantation
P
1986‐1996 1996‐2006 2006‐2016
N = 1869 N = 2157 N = 2003
Age
Overall 53.9 (47.3‐59.4) 55.7 (49.0‐61.4) 56.1 (48.4‐62.4) <0.001
Female 53.6 (47.1‐59.1) 55.6 (49.0‐61.4) 55.9 (48.6‐62.3) <0.001
Male 55.6 (47.3‐59.4) 57.0 (48.1‐62.1) 56.9 (48.4‐62.4) 0.616
Gender (%)
Female 1664 (89.0) 1904 (88.3) 1699 (84.8) 0.532
Male 205 (11.0) 253 (11.7) 304 (15.2)
PBC (%)
PBC 1866 (99.8) 2123 (98.4) 1918 (95.8) <0.001
PBC — AIH 0 (0.0) 10 (0.5) 28 (1.4)
PBC — HCC 3 (0.2) 24 (1.1) 57 (2.8)
MELD score 17.0 (13.8‐20.5) 15.3 (12.3‐19.1) 16.8 (12.8‐21.7) <0.001
Creatinine (mg/dL) 1.0 (0.81‐1.26) 0.9 (0.8‐1.1) 0.80 (0.6‐1.1) <0.001
Bilirubin (mg/dL) 7.2 (3.5‐13.2) 5.4 (2.7‐10.3) 6.0 (2.6‐12.9) 0.001
INR 1.2 (1.1‐1.5) 1.2 (1.1‐1.4) 1.3 (1.1‐1.6) <0.001
PBC, primary biliary cholangitis; AIH, autoimmune hepatitis; HCC, hepatocellular carcinoma; MELD, model for end‐stage liver disease; INR, international
normalised ratio.
Data are shown as median (IQR). Missing values: Age: 13 (0.2%), gender: 1 (0.02%), transplantation indication: 0 (0%), MELD score: 3280 (54.4%), crea-
tinine: 2957 (49.0%), bilirubin: 3199 (53.0%), INR: 3534 (58.6%).
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Thereafter, the annual transplant rate for PBC decreased to an aver-
age of 200 in the last decade (Figure 1B). These changes correspond
with an average annual increase of 21.5 (95% CI 21.3‐21.7;
P < 0.001) transplantations in the first decade, followed by a
decrease of −1.9 (95% CI −2.1 to −1.7; P < 0.001) in the second
decade, and a marginal annual decrease of −0.3 (95% CI −0.5 to
−0.1; P = 0.002) in the last decade.
The proportion of patients undergoing liver transplantation for
PBC as compared to other indications decreased from 20.3% in
1986% to 3.7% in 2015 (Figure 2A). The greatest decrease was in
the first decade, with an annual proportional decrease of 0.9% (95%
CI −0.92 to −0.88; P < 0.001). Thereafter, the proportion of trans-
plantations for PBC annually decreased with 0.3% (95% CI −0.343
to −0.337; P < 0.001) in the second decade and 0.1% (95% CI
−0.064 to −0.057; P < 0.001) in the third decade. No other leading
disease aetiology showed a persistent significant proportional
decrease over all three decades (Figure 2B).
3.3 | Age
The overall median age at time of transplantation was 55 years (in-
terquartile range [IQR] 48‐61) for patients with PBC, and 53 years
(IQR 44‐59) for non‐PBC patients (P<.001). For PBC patients, the
median age at time of transplantation increased significantly from
54 (IQR 47‐59) in the first decade to 56 (IQR 49‐61) in the second
decade (P < 0.001), while no significant age difference was found
thereafter (P = 0.255) (Figure 3). Furthermore, a change in distribu-
tion of patients’ age at time of transplantation was found (Figure 4).
The proportion of patients aged >60 increased from 23% in the first
decade to 35% in the last decade (P > 0.001), whereas the
7000 Unknown (n = 1835)
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proportion of patients between 40‐49 and 50‐59 years decreased
from 27% and 42% in the first decade, to 21% and 36% respectively
in the last decade (both P < 0.001).
3.4 | Gender
A total of 761 (12.6%) male and 5267 (87.4%) female patients with
PBC were transplanted, corresponding to a male to female ratio of
1:6.9. For non‐PBC aetiologies, 74 484 (69.7%) males and 32 348
(30.3%) females underwent transplantation, corresponding to a
female to male ratio of 1:0.43. In PBC patients, the proportion of
transplantations for males increased significantly from 11.0% in the
first decade to 15.1% in the third decade (P < 0.001) (Figure 5). In
the first decade, males were significantly older than females with a
median age of 56 years (IQR 49‐61) and 55 years (IQR 48‐60)
respectively (P < 0.05), but no differences were found in the second
(P = 0.755) and third decades (P = 0.695) (Figure S1A).
3.5 | MELD scores
In patients with PBC, the median MELD score at time of transplanta-
tion increased from 15.3 (IQR 12.2‐19.2) in the second decade to
16.8 (IQR 12.8‐21.6) in the last decade (P < 0.001). An increase in
MELD score between these decades was also found in non‐PBC
liver transplantations, in which the median MELD score increased
from 15.6 (IQR 11.7‐21.2) to 16.1 (IQR 11.1‐23.0) (P < 0.001)
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(A)
(B)
20
Pr
op
or
tio
n 
(%
)
Pr
op
or
tio
n 
(%
)
15
10
Year of transplantation
PBC
Viral hepatitis
Alcoholic cirrhosis
Cancers
non-PBC
auto-immune disease
30
25
20
15
10
5
0
5
0
19
86
19
87
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Year of transplantation
19
86
19
87
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
F IGURE 2 Proportion of liver
transplantations in ELTR centres from
1986 to 2016 for (A) PBC and (B) PBC and
other leading indications. ELTR, European
Liver Transplant Registry; PBC, primary
biliary cholangitis
HARMS ET AL. | 289
(Figure 5). There were no significant differences in MELD scores
between PBC and non‐PBC patients in either the second or the third
decade (P = 0.101 and P = 0.119 respectively). In PBC patients, no
significant difference in MELD score was found between females
(16.1, IQR 12.5‐20.8) and males (16.9, IQR 13.0‐21.0) (P = 0.160).
3.6 | Characterisation of Nationwide Cohort
3.6.1 | Mortality on the waiting list
From 1 January 1986 to 31 December 2015, 184 patients with PBC
were placed on the waiting list for transplantation in the Nether-
lands. Of this total, one patient (0.5%) was alive without transplanta-
tion at the end of follow up. Twenty‐nine (15.8%) patients died on
the waiting list or were removed from the waiting list due to clinical
deterioration. Eight of these events occurred between 1986 and
1995, eight between 1996 and 2005, and 13 between 2006
and 2015, corresponding with a waiting list mortality of 12%, 16%,
and 33% in the consecutive decades. In addition, three (1.6%)
patients were removed at personal request or due to improved con-
dition. The remaining 151 (82.1%) were transplanted.
3.6.2 | Study population
Characteristics and biochemistry of the 151 patients who were
transplanted for PBC in the Netherlands are presented in Table S1.
The median age at the time of transplantation was 54 years (IQR
48‐59). Transplanted patients were diagnosed with PBC at a med-
ian age of 46 (IQR 40‐51), and listed at a median age of 53 (IQR
47‐59). Males were significantly older than females at the time of
transplantation, with a median age of 58 (IQR 53‐64) as compared
to 53 (IQR 49‐58) (P = 0.006), while the MELD score at the time
of liver transplantation did not differ between the sexes
(P = 0.838).
3.6.3 | Primary indications for liver transplantation:
Absolute changes over time
The absolute number of transplantations for PBC nearly halved over
time, from 65 in the first decade to 36 in the third decade
(P < 0.001) (Figure S2). Of the 151 patients transplanted for PBC,
129 (85.4%) were listed for the primary indication PBC alone, 16
(10.6%) patients had a PBC‐AIH overlap syndrome, and six (4.0%)
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patients had an additional diagnosis of hepatocellular carcinoma. The
proportion of patients with PBC transplanted due to poor quality of
life significantly increased from 2% to 12% to 17% in the three con-
secutive decades (P = 0.004).
3.6.4 | UDCA treatment and response for all
patients with PBC
A total of 102 (67.5%) transplanted patients were treated with
UDCA at the time of listing. The proportion of patients who were
treated with UDCA increased significantly over time, from 37% in
the first, to 92% in the last decade (P < 0.001). Table 2 shows the
biochemical response for these UDCA‐treated patients according to
the Barcelona, Paris I, and GLOBE response criteria.14,20,24,25 In this
cohort of transplanted patients with PBC, 6‐47% of patients showed
a biochemical response to treatment, depending on the response cri-
teria. The Paris I criteria identified the lowest percentage of com-
plete biochemical responders after 12 months of UDCA treatment
(6%). When classification by different response criteria was com-
pared, this proportion was significantly lower than the percentage of
complete responders as classified by the Barcelona criteria (30%)
(P = 0.008) and by the GLOBE criteria (28%) (P = 0.004).
4 | DISCUSSION
This study represents the largest European‐wide study on time
trends in liver transplantations for PBC to date, covering the past
30 years. The percentage of transplantations for PBC as compared
to other aetiologies decreased to less than one‐fifth of its original
proportion of 20%. In contrast, the absolute number of
transplantations for PBC has remained virtually stable over the last
10 years. Characteristics of patients undergoing transplantation for
PBC have changed over time, whereby they are now older, have
higher MELD scores, and are more likely to be male than 30 years
ago. However, differences over time were quantitatively small.
The current study is the first to demonstrate a stable annual
absolute number of transplantations for PBC over the past 10 years
in Europe. This result confirms that today, in a minority of patients,
we are still unable to prevent liver failure which underlines the
necessity of additional therapeutic options for this group. A study by
Lee et al that assessed transplantations trends for PBC in the United
States showed an absolute annual decrease without reaching a
steady state, but their study period only covered 11 years and ended
in 2006.13 Our finding seems in contrast to the recent study by
Webb et al reporting a decrease in the United Kingdom and the Uni-
ted States up until 2014. However, a true comparison is difficult,
since the latter study only reported listings for transplantation and
not actual liver transplantation, and measured numbers as a ratio
against the total (increasing) general population. However, the steady
absolute number of transplantations for PBC is also discordant with
an overall increase in overall numbers of annual transplantations and
with the increasing prevalence of PBC over the past decades.3,4
Therefore, the stable absolute number of transplantations for PBC
that we report could possibly be interpreted as a relative decrease.
Although we found an annual number of approximately 200
transplantations for PBC over the past 10 years the true number of
PBC patients in need of liver transplantation may be higher. First,
16% of all listed patients with PBC in our secondary analysis in the
Dutch cohort died while on the waiting list for transplantation or
were removed due to deteriorating clinical condition. This result is in
line with a recent study showing a waiting list mortality of 12% for
100
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PBC patients, which was higher than for most other aetiologies.26
Second, as compared to the number of Dutch patients who under-
went transplantation for PBC reported in the ELTR database, we
identified an additional 10% of patients after extensive review of
medical records of all listed patients in the entire Dutch cohort. Evi-
dently, not all transplanted patients with PBC had been reported as
such, and were possibly labelled with more general aetiologies lack-
ing further specification, such as cirrhosis or autoimmune disorders.
Even more so, a minority of patients might have been incorrectly
diagnosed when PBC was not recognised by treating physicians as
the underlying cause of cirrhosis. Furthermore, within the top five
primary indications for transplantation, PBC was the only one that
showed a constant proportional decrease over three decades. We
speculate that several factors may have contributed to this decrease.
First is the possible influence of UDCA treatment. Recently, the Glo-
bal PBC Study Group reported a strong association between UDCA
treatment and improved transplant‐free survival.11 The number of
transplantations for PBC peaked several years after UDCA was
introduced in the early nineties, with a subsequent much more stable
number of transplantations. Second, the introduction of urgency‐
based allocation may have influenced the proportional decrease in
transplantations for PBC. Since MELD‐based allocation in 2006,
patients’ time on the waitlist is no longer a factor in allocation, possi-
bly impeding the chance of receiving a transplantation for patients
with a relatively slowly progressing disease such as PBC.1
We also identified several changes in the characteristics of
patients undergoing transplantation for PBC over the past three dec-
ades. We found an increase in age at time of transplantation. This was
in line with the results from a long‐term study from Birmingham and a
recent larger study covering both the UK and the USA.16,27 Most
noticeable, however, was our finding of an increasing proportion of
patients with PBC transplanted at age >60 years. This may be related
to an overall improved medical care and physical condition, permitting
transplantation at higher ages. The influence of possible changes in
environmental triggers involved in the development of PBC should
also be considered, especially since a recent large study showed that
the age at PBC diagnosis has markedly increased over the years.28
However, with a median age at diagnosis of 46 years in patients with
PBC listed for transplantation within our in‐depth population, this pop-
ulation undergoing liver transplantation for PBC was much younger at
diagnosis than the large overall cohorts reported by the Global PBC
Study Group (55 years) and the UK‐PBC Study Group (55 years).21,29
This suggests that young patients may be more likely to develop end‐
stage disease requiring liver transplantation, as has previously been
reported.30 Furthermore, we found that an increasing number of males
were transplanted for PBC over time, which was also reported in the
United States.27 The increasing male to female ratio reported in
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F IGURE 5 A, MELD scores at time of transplantation for patients
with PBC in Europe from 1996 to 2015; B, MELD scores of patients
transplanted for PBC vs non‐PBC aetiologies in 1996‐2005 vs 2006‐
2015. MELD scores are reported as median with their interquartile
ranges. As a result of a lack of biochemical data from the first
decade of the study period, data are shown for 1996‐2015. In this
period, MELD scores were available for 2749 (46%) of patients with
PBC and 51 410 (48%) of non‐PBC patients
TABLE 2 Biochemical response to 12 months of UDCA therapy
in patients who underwent liver transplantation in the Netherlands
between 1986 and 2016
Decade of liver transplantation
1986‐1996 1996‐2006 2006‐2016
N = 28 N = 41 N = 33
Barcelona criteria
Responder 3 (20) 10 (40) 3 (21)
Incomplete responder 12 (8) 15 (60) 11 (79)
Paris I criteria
Responder 1 (5) 1 (4) 2 (10)
Incomplete responder 19 (95) 26 (96) 18 (90)
GLOBE criteria
Responder 0 (0) 9 (39) 7 (39)
Incomplete responder 16 (100) 14 (61) 11 (61)
Data are shown as n (%). Missing values: Barcelona criteria: 48 (47%),
Paris I criteria: 37 (36%), GLOBE criteria: 45 (44%).
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epidemiological studies could contribute to these findings, as well as
data that suggest males are less likely to respond well to treatment
with UDCA.30,31 The MELD score at time of transplantation was
slightly but significantly higher after 2006, as compared to the period
between 1996 and 2005. This might be explained by the introduction
of MELD‐based allocation in 2006. This increase was found for both
PBC and non‐PBC patients, although more pronounced in patients
with PBC. We identified no differences in MELD scores between PBC
and non‐PBC patients.
In our in‐depth analysis of the Dutch cohort, the patients' charac-
teristics were comparable to the European‐wide cohort. Notably, we
found that the proportion of patients with PBC who underwent trans-
plantation for poor quality of life increased from 2% before 1995 to
17% in the last decade. Furthermore, we found that despite interna-
tional guidelines recommending that all patients with PBC be treated
with UDCA,32,33 8% were not treated with UDCA during the last dec-
ade. Although we were unable to validate these findings in the Euro-
pean data, these factors might also have impacted the remaining
number of liver transplantations for PBC over the last decade.
To the best of our knowledge, our study was the first to assess
time trends in liver transplantation for PBC throughout Europe over a
sizeable period of 30 years, during which UDCA was introduced as the
standard of care. We were able to include all liver transplantations
reported to the ELTR, resulting in a large population of 6029 trans-
planted PBC patients. The additional nationwide in‐depth analysis over
the same study period enabled us to characterise the population in
need for liver transplantation more extensively over time. However,
some limitations should be taken into account. Biochemical data were
incomplete in both the ELTR data and the Dutch in‐depth analysis.
However, due to the large population and the similar patterns found in
both analyses, we believe this has not introduced an important bias.
Second, our in‐depth analyses are based on data of Dutch patients
only and the extent to which findings can be generalised is uncertain.
Nevertheless, since patient characteristics and MELD scores at trans-
plantation were comparable to the PBC population in the ELTR data-
base and similar transplantation patterns over time were observed, the
results of our nationwide in‐depth analyses may well be representative
of the European PBC population in need of liver transplantation.
In conclusion, we found that, despite a relative decrease, the
absolute number of transplantations for PBC has reached a steady
state. Still, over 200 European patients with PBC undergo liver
transplantation annually. These patients are slightly older,
have higher MELD scores, and are more likely to be male than
30 years ago. Effective second‐line therapies may further reduce the
need for liver transplantation in patients with PBC in the future.
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